Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 4/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.77 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.63 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.63 |
| ▸ | HRH1 | P35367 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | ESR1 | P03372 | 1/20 | 0.63 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.63 |
| ▸ | HRH2 | P25021 | 1/20 | 0.63 |
| ▸ | HTR2A | P28223 | 1/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.63 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.63 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.63 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13175653 | 1.00 | CHRM2 (0.77) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| SCHEMBL14709412 | 1.00 | CHRM2 (0.77) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| Fumaric Acid SCHEMBL14696873 | 0.95 | CHRM2 (0.70) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| Fumaric Acid SCHEMBL14696874 | 0.95 | CHRM2 (0.70) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| SCHEMBL4859538 | 0.92 | CHRM2 (0.66) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| SCHEMBL4879639 | 0.92 | CHRM2 (0.67) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| SCHEMBL574530 | 0.92 | CHRM2 (0.67) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| Hydrochloric Acid SCHEMBL4771342 | 0.91 | CHRM2 (0.66) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| SCHEMBL2448532 | 0.89 | CHRM2 (0.72) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| SCHEMBL222314 | 0.88 | CHRM2 (0.62) | CHRM2CHRM1CHRM3CHRM5HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110171274-A1 | Fesoterodine Substantially Free of Dehydroxy Impurity | ACTAVIS GROUP PTC EHF (IS) | 2011-07-14 | — | — | US | claimed |
| EP-2855421-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 3,3-DIPHENYLPROPYLAMINES | CRYSTAL PHARMA SAU (ES) | 2018-03-21 | — | — | EP | disclosed |
| US-9751828-B2 | Antimuscarinic compound having a low content of impurities | DIPHARMA FRANCIS S.R.L. (IT) | 2017-09-05 | — | — | US | disclosed |
| US-9751828-B2 | Antimuscarinic compound having a low content of impurities | DIPHARMA FRANCIS S.R.L. (IT) | 2017-09-05 | — | — | US | disclosed |
| US-9440910-B2 | Reference markers for fesoterodine fumarate | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2016-09-13 | — | — | US | disclosed |
| US-9440910-B2 | Reference markers for fesoterodine fumarate | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2016-09-13 | — | — | US | disclosed |
| EP-2545024-B1 | PROCESS FOR PREPARATION OF 3-(2-HYDROXY-5-SUBSTITUTED PHENYL)-3-PHENYLPROPYLAMINES, INTERMEDIATES FOR MAKING HYDROXYTOLTERODINE AND FESOTERODINE | LEK PHARMACEUTICALS (SI) | 2016-08-03 | — | — | EP | disclosed |
| US-20160031796-A1 | ANTIMUSCARINIC COMPOUND HAVING A LOW CONTENT OF IMPURITIES | DIPHARMA FRANCIS S.R.L. (IT) | 2016-02-04 | — | — | US | disclosed |
| US-20160031796-A1 | ANTIMUSCARINIC COMPOUND HAVING A LOW CONTENT OF IMPURITIES | DIPHARMA FRANCIS S.R.L. (IT) | 2016-02-04 | — | — | US | disclosed |
| US-20150175526-A2 | THE NOVEL REFERENCE MARKERS FOR FESOTERODINE FUMARATE | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2015-06-25 | — | — | US | disclosed |
| WO-2010010464-A2 | FESOTERODINE SUBSTANTIALLY FREE OF DEHYDROXY IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010010464-A2 | FESOTERODINE SUBSTANTIALLY FREE OF DEHYDROXY IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2010-01-28 | — | — | WO | disclosed |
| EP-1461306-B1 | QUATERNARY AMMONIUM COMPOUNDS AND THEIR USE AS ANTIMUSCARINIC AGENTS | PHARMACIA & UPJOHN CO LLC (US) | 2008-12-24 | — | — | EP | disclosed |
| EP-1461306-B1 | QUATERNARY AMMONIUM COMPOUNDS AND THEIR USE AS ANTIMUSCARINIC AGENTS | PHARMACIA & UPJOHN CO LLC (US) | 2008-12-24 | — | — | EP | disclosed |
| US-7439397-B2 | reacting methyl bromide and 2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-(trifluoromethyl) phenol; formation of (3R)-3-[2-hydroxy-5-(trifluoromethyl)phenyl]-N,N-diisopropyl-N-methyl-3-phenylpropan-1-aminium bromide; asthma, chronic obstructive pulmonary disorder, allergic and infectious rhinitis | PFIZER INC (US) | 2008-10-21 | — | — | US | disclosed |
| US-20050148672-A1 | Quaternary ammonium compounds | RICHARDS IVAN (US) | 2005-07-07 | — | — | US | disclosed |
| US-6890920-B2 | Quaternary ammonium compounds | PHARMACIA & UPJOHN COMPANY (US) | 2005-05-10 | — | — | US | disclosed |
| US-20040220224-A1 | Method of treating irritable bowel syndrome | PFIZER INC | 2004-11-04 | — | — | US | disclosed |
| US-20040209916-A1 | Combination therapies | PFIZER INC | 2004-10-21 | — | — | US | disclosed |
| US-20030158176-A1 | Quaternary ammonium compounds | PHARMACIA & UPJOHN COMPANY | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031796-A1 | ANTIMUSCARINIC COMPOUND HAVING A LOW CONTENT OF IMPURITIES | ADRA2B, ADRB2, ADRA1B | CHRM2 9/4885CHRM1 60/4885CHRM3 4/4885 |
| US-20040209916-A1 | Combination therapies | ADRA2C, ADRB2, ADRA2A | CHRM2 30/4885CHRM1 33/4885CHRM3 32/4885 |
| US-20150175526-A2 | THE NOVEL REFERENCE MARKERS FOR FESOTERODINE FUMARATE | SHBG, FES, KLK3 | CHRM2 163/4885CHRM1 739/4885CHRM3 146/4885 |
| US-20030158176-A1 | Quaternary ammonium compounds | CLIC1, CLIC4, CORO1C | CHRM2 157/4885CHRM1 27/4885CHRM3 129/4885 |
| US-20050148672-A1 | Quaternary ammonium compounds | BET1, EP300, BRD4 | CHRM2 2552/4885CHRM1 985/4885CHRM3 2026/4885 |
| US-20040220224-A1 | Method of treating irritable bowel syndrome | SI, VIP, SLC10A2 | CHRM2 950/4885CHRM1 1033/4885CHRM3 897/4885 |
| US-20110171274-A1 | Fesoterodine Substantially Free of Dehydroxy Impurity | HSD17B7, CYP17A1, CYP21A2 | CHRM2 729/4885CHRM1 786/4885CHRM3 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.